One group found that by combining Avasimibe with a KRAS multi-peptide vaccine in prophylactic mouse models, a significant decrease in tumour volume was seen compared to monotherapies, with an increase in CD8+ T cell levels in the TME (126). The gene discussed is KRAS; the disease is neoplasm.